Let’s do more for patients, together
Our commitment to innovation and quality relationships leads to longstanding and valuable partnerships through clinical studies, targeted applications of our multiomics platform, quality improvement initiatives, and more.
Biopharma Partners
Putting patients first means we champion the research and development of early stage treatments and precision therapies throughout the care continuum.
We partner with biopharma companies to leverage our platform’s capabilities and develop targeted therapies through:
- Biomarker discovery
- Treatment monitoring
- Predicting treatment response
- Measurable residual disease (MRD) detection
- Multiomics data generation in new disease areas
A selection of our work with biopharma partners
Siemens Healthineers
To identify suitable markers for early breast cancer detection
Merck KGaA, Darmstadt, Germany
To identify signatures of non-small cell lung cancer
Research Partners
Our partnerships with organizations throughout the healthcare ecosystem—from academic institutions, to healthcare systems, providers, health plans, and more—are critical to advance early detection technology for patients and ensure that our tests are seamlessly integrated into clinical care and accessible by all.
A selection of our work with research partners
Morehouse School of Medicine
To increase clinical study participation among Black patients
Oracle Cerner and Elligo Health Research
To increase access to cancer clinical trials